Bubendorf, Switzerland, December 2016 — CIS Pharma welcomes Dr. Christophe Thommen, who will lead the research team as the new head of research and laboratory operations. Christophe is an expert in natural products chemistry and his expertise has already led to a number of innovative and efficient syntheses in the industry. With his focus on scalability and industrialization of synthesis steps, he is of great value for advancing the rich research portfolio to the next stages.

About antibody-drug conjugates

Antibody-drug conjugates, or ADCs, are a class of highly potent drugs for the treatment of cancer. ADCs are composed of an antibody that is linked to an anti-cancer payload. The conjugates target cancer cells. Due to the high affinity of the antibodies to tumor cells, the cytotoxic payload is delivered specifically to the cancer tissue, reducing harmful side effects associated with traditional chemotherapeutic agents.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.